CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-864-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees124
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions
What is CASI Pharmaceuticals' stock symbol?
CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."
How were CASI Pharmaceuticals' earnings last quarter?
CASI Pharmaceuticals Inc (NASDAQ:CASI) released its earnings results on Friday, August, 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. View CASI Pharmaceuticals' Earnings History.
When is CASI Pharmaceuticals' next earnings date?
What price target have analysts set for CASI?
1 equities research analysts have issued 12-month price objectives for CASI Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 113.4% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.
What is the consensus analysts' recommendation for CASI Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.
Has CASI Pharmaceuticals been receiving favorable news coverage?
Media stories about CASI stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for CASI Pharmaceuticals.
Who are some of CASI Pharmaceuticals' key competitors?
Some companies that are related to CASI Pharmaceuticals include Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI), Fate Therapeutics (FATE), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Rubius Therapeutics (RUBY), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA) and Vericel (VCEL).
What other stocks do shareholders of CASI Pharmaceuticals own?
Who are CASI Pharmaceuticals' key executives?
CASI Pharmaceuticals' management team includes the folowing people:
- Dr. Wei-Wu He, Chairman & CEO (Age 54)
- Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
- Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
- Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
- Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)
How do I buy shares of CASI Pharmaceuticals?
Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CASI Pharmaceuticals' stock price today?
One share of CASI stock can currently be purchased for approximately $3.28.
How big of a company is CASI Pharmaceuticals?
CASI Pharmaceuticals has a market capitalization of $313.96 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.
What is CASI Pharmaceuticals' official website?
How can I contact CASI Pharmaceuticals?
CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]
MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
